You are here

ANTIBODIES TO HUMAN NM23: A POTENTIAL MARKER OF MALIGNANCY

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 13714
Amount: $500,000.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1991
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
19 Firstfield Rd
Gaithersburg, MD 20878
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Charles R King
 (301) 590-2600
Business Contact
Phone: () -
Research Institution
N/A
Abstract

FOR MANY TYPES OF CANCER, PATIENT MORBIDITY-AND ULTIMATELY MORTALITY-IS DUE TO THE DEVELOPMENT OF METASTATIC LESIONS. EXPERIMENTAL EVIDENCE SUGGESTS THAT TUMORS CAN INHERENTLY DIFFER IN THEIR ABILITY TO FORM METASTASIS. AS YET THERE ISNO AVAILABLE TEST TO DETERMINE IF PARTICULAR HUMAN TUMORS ARE OF HIGH OR LOW METASTATIC POTENTIAL. RECENT EVIDENCE SUGGESTS THAT THE EXPRESSION OF THE NM23 GENE IS RELATED INVERSELY TO THE METASTATIC ABILITY OF A NUMBER OF TUMOR CELLS. THIS RESEARCH WILL TRANSFER THE NM23PROTEIN CODING SEQUENCE TO A BACTERIAL EXPRESSION PLASMID. THE EXPRESSED NM23 PROTEIN WILL BE ISOLATED AND USED IN THE GENERATION OF POLYCLONAL AND MONOCLONAL ANTIBODIES. IN PHASE II, THE RESEARCH WILL TEST WHETHER THESE ANTIBODIES CAN BE USED TO DETERMINE THE LEVEL OF NM23 PROTEIN IN TUMOR SAMPLES, AND WHETHER THIS LEVEL IS ASSOCIATED WITH METASTATIC PROPENSITY OF A TUMOR.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government